{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:07:17Z","timestamp":1762265237382,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","award":["IN-ES-987-5349"],"award-info":[{"award-number":["IN-ES-987-5349"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016391","name":"Societat Catalana de Digestologia","doi-asserted-by":"publisher","award":["2017_SGR_1753"],"award-info":[{"award-number":["2017_SGR_1753"]}],"id":[{"id":"10.13039\/501100016391","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008318","name":"Spanish Association for the Study of the Liver","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016658","name":"National Plan on Drugs","doi-asserted-by":"publisher","award":["MSA_PNSD2020"],"award-info":[{"award-number":["MSA_PNSD2020"]}],"id":[{"id":"10.13039\/100016658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.gastrohep.2024.502288","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:24:24Z","timestamp":1731554664000},"page":"502288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Externalized nurse-led model for hepatitis C virus microelimination and impact of drug use profile"],"prefix":"10.1016","volume":"48","author":[{"given":"Anna","family":"Miralpeix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Colomera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Major","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Colom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2024.502288_bib0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.gastrohep.2019.09.002","article-title":"Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)","volume":"42","author":"Crespo","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0105","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl.","key":"10.1016\/j.gastrohep.2024.502288_bib0110","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0115","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/cid\/ciz696","article-title":"Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis","volume":"70","author":"Graf","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0120","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 \u2013 what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0130","unstructured":"World Health Organization (2016). Combating hepatitis B and C to reach elimination by 2030: advocacy brief. https:\/\/apps.who.int\/iris\/handle\/10665\/206453 [accessed 01.7.23]."},{"key":"10.1016\/j.gastrohep.2024.502288_bib0135","unstructured":"European Centre for Disease Prevention and Control (2018). Public health guidance on HIV, hepatitis B and C testing in the EU\/EEA \u2013 an integrated approach. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/hiv-hep-testing-guidance_0.pdf [accessed 01.7.23]."},{"key":"10.1016\/j.gastrohep.2024.502288_bib0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade","volume":"286","author":"Lazarus","year":"2019","journal-title":"J Intern Med"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0145","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/phn.13092","article-title":"Treating people where they are: nurse-led micro-elimination of hepatitis C in supported housing sites for networks of people who inject drugs in Victoria, Canada","volume":"39","author":"Selfridge","year":"2022","journal-title":"Public Health Nurs (Boston, Mass)"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugpo.2019.01.012","article-title":"Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs","volume":"66","author":"Day","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study","volume":"26","author":"Litwin","year":"2019","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0160","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/10826084.2020.1846198","article-title":"Reasons for not seeking hepatitis C treatment among people who inject drugs","volume":"56","author":"Morris","year":"2021","journal-title":"Substance Use Misuse"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8weeks in treatment-na\u00efve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial","volume":"72","author":"Brown","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0170","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0175","doi-asserted-by":"crossref","first-page":"100580","DOI":"10.1016\/j.jhepr.2022.100580","article-title":"HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates","volume":"4","author":"Lens","year":"2022","journal-title":"JHEP Rep Innov Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/add.14569","article-title":"The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England","volume":"114","author":"Harrison","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2019.02.009","article-title":"Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: a pilot study","volume":"69","author":"Norton","year":"2019","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.gastrohep.2024.502288_bib0190","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet (London, England)"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524003005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524003005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:02:23Z","timestamp":1762264943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570524003005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0210570524003005"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502288","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Externalized nurse-led model for hepatitis C virus microelimination and impact of drug use profile","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502288"}}